20 completed, 3 terminated, 3 unknown, 1 recruiting. 9 Phase 2, 9 Phase 3, 4 Not applicable, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Completed 8, Terminated 1 |
| Phase 3 | 9 | Completed 7, Terminated 2 |
| Not applicable | 4 | Completed 2, Recruiting 1, Unknown 1 |
| Phase 1 | 3 | Completed 2, Terminated 1 |
Follow Jacobs syndrome: new trials by email Literature Review of Jacobs syndrome trials Research Report on Jacobs syndrome
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The Predictive Value of Lubricin in Patients With Infective Endocarditis Lubricin - Infective Endocarditis | Unknown | Aydin Adnan Menderes University | 60 | 2024-02-11 | 2024-02-20 | |
| Avatrombopag vs. Placebo for CIT in GI Malignancies Avatrombopag, Matching Placebo - Gastrointestinal Cancer, Gastrointestinal Neoplasms | Phase 2 | Completed | Hanny Al-Samkari, MD | 49 | 2023-11-01 | 2026-08-31 |
| Contribution of Anti-platelet Antibodies Identified With MAIPA Assay in the Demonstration of the Auto-immune Character of a Thrombocytopenia at Diagnosis Blood samples - Thrombocytopenia, Immune Thrombocytopenia | Not applicable | Recruiting | University Hospital, Bordeaux | 225 | 2021-05-19 | 2026-06-01 |
| Eltrombopag vs. rhTPO to Increase Platelet Level After HSCT Eltrombopag, rhTPO - Eltrombopag, Hematopoietic Stem Cell Transplantation | Phase 3 | Completed | Shenzhen Second People's Hospital | 98 | 2018-07-01 | 2022-07-27 |
| Safety and Efficacy of 2 Concentrations of Lubricin vs Sodium Hyaluronate in Ocular Discomfort After Refractive Surgery. Lubricin 20µg/ml, Lubricin 50µg/ml, Sodium hyaluronate 0.18% - Ocular Discomfort | Not applicable | Completed | Dompé Farmaceutici S.p.A | 30 | 2017-06-17 | 2024-12-06 |
| A Study to Assess the Safety and Efficacy of Eltrombopag in Japanese Subjects With Refractory, Moderate or More Severe Aplastic Anemia Eltrombopag 12.5 mg, Eltrombopag 25 mg - Cytopaenia | Phase 2 | Completed | Novartis Pharmaceuticals | 21 | 2014-07-23 | 2019-05-03 |
| A Study of Eltrombopag or Placebo in Combination With Azacitidine in Subjects With International Prognostic Scoring System (IPSS) Intermediate-1, Intermediate-2 or High-risk Myelodysplastic Syndromes (MDS) Eltrombopag, Azacitidine, Placebo - Thrombocytopaenia | Phase 3 | Terminated | Novartis Pharmaceuticals | 356 | 2014-06-10 | 2017-12-12 |
| A Phase 2 Study to Evaluate the Efficacy and Safety of AMG531 in Aplastic Anemia AMG531 - Aplastic Anemia | Phase 2 | Completed | Kyowa Kirin Korea Co., Ltd. | 35 | 2014-04-14 | 2024-04-30 |
| Effectiveness of a Simplified Short Regimen for Multidrug Resistant Tuberculosis in Uzbekistan Short course MDR-TB treatment regimen - Multidrug Resistant Tuberculosis | Unknown | Medecins Sans Frontieres, Netherlands | 110 | 2013-09-01 | 2015-07-14 | |
| Comparing Intermediate-dose CTX+ G-CSF Plus or Not rhTPO for PB CD34+ Cells Mobilization in MM Patients rhTPO, CTX, -CSF - Multiple Myeloma | Not applicable | Unknown | Wang Guorong | 200 | 2013-01-01 | 2017-02-09 |
| Trial of Eltrombopag During Consolidation Therapy in Adults With AML in Complete Remission Phase I- Cytarabine & Eltrombopag, Phase II- Sequence A, Phase II- Sequence B - Acute Myeloid Leukemia | Phase 1 / Phase 2 | Terminated | PrECOG, LLC. | 15 | 2012-07-01 | 2020-11-03 |
| A Retrospective Chart Review of Thirty Three Children Who Have Received Clinical Treatment With Either Romiplostim or Eltrombopag From 2009-2013 Immune Thrombocytopenia | Completed | Weill Medical College of Cornell University | 33 | 2012-01-01 | 2017-02-01 | |
| Phase II Eltrombopag in Chronic Lymphocytic Leukemia (CLL) Eltrombopag - CLL, Leukemia | Phase 2 | Completed | M.D. Anderson Cancer Center | 23 | 2010-11-03 | 2023-03-23 |
| Clinical Trial for Non-responders Who Previously Participated in Eltrombopag Studies TPL 103922 or TPL 108390 Eltrombopag, Antiviral therapy - Hepatitis C | Phase 3 | Completed | GlaxoSmithKline | 27 | 2009-09-01 | 2013-12-06 |
| Eltrombopag Treatment of Thrombocytopenia in Subjects With Advanced Myelodysplastic Syndrome (MDS) or Secondary Acute Myeloid Leukemia After MDS (sAML/MDS) eltrombopag olamine, Placebo - Myelodysplastic Syndrome | Phase 1 | Completed | GlaxoSmithKline | 98 | 2009-05-14 | 2017-11-13 |
| Eltrombopag To Reduce The Need For Platelet Transfusion In Subjects With Chronic Liver Disease And Thrombocytopenia Undergoing Elective Invasive Procedures Eltrombopag, Placebo - Non-alcoholic Steatohepatitis, Chronic Liver Disease | Phase 3 | Terminated | GlaxoSmithKline | 292 | 2008-06-01 | 2018-10-12 |
| Eltrombopag To Initiate And Maintain Interferon Antiviral Treatment To Subjects With Hepatitis C Related Liver Disease eltrombopag, placebo - Hepatitis C, Chronic | Phase 3 | Completed | GlaxoSmithKline | 687 | 2007-10-01 | 2013-11-05 |
| Eltrombopag To Initiate And Maintain Interferon Antiviral Treatment To Benefit Subjects With Hepatitis C Liver Disease eltrombopag, placebo - Hepatitis C, Chronic | Phase 3 | Completed | GlaxoSmithKline | 759 | 2007-10-01 | 2013-11-05 |
| Clinical Evaluation of SB-497115-GR in Chronic Idiopathic Thrombocytopenic Purpura (ITP) SB-497115-GR 12.5mg, SB-497115-GR 25mg, SB-497115-GR 12.5mg matching placebo - Chronic Idiopathic Thrombocytopenic Purpura, Purpura, Thrombocytopenic, Idiopathic | Phase 3 | Completed | GlaxoSmithKline | 23 | 2007-09-01 | 2011-03-30 |
| Romiplostim (AMG 531) Versus Medical Standard of Care for Immune (Idiopathic) Thrombocytopenic Purpura Medical Standard of Care for ITP, Romiplostim - Idiopathic Thrombocytopenic Purpura, Thrombocytopenia | Phase 3 | Completed | Amgen | 234 | 2006-12-01 | 2022-11-08 |
Showing 20 of 27. Sign in to see all of them.
Thrombocytopenia (16) · Purpura, Thrombocytopenic, Idiopathic (6) · Hepatitis C (5) · Hepatitis C, Chronic (3) · Anemia, Aplastic (2) · Hematologic Diseases (2) · Hemostatic Disorders (2) · Leukemia (2) · Myelodysplastic Syndromes (2) · Purpura, Thrombocytopenic (2) · Acquired Immunodeficiency Syndrome (1) · Anemia, Refractory, with Excess of Blasts (1) · Endocarditis (1) · Gastrointestinal Neoplasms (1)
Hemic and Lymphatic Diseases (20) · Blood Platelet Disorders (19) · Cytopenia (19) · Hematologic Diseases (18) · Pathologic Processes (11) · Pathological Conditions, Signs and Symptoms (11) · Immune System Diseases (9) · Digestive System Diseases (7) · Hemorrhagic Disorders (7) · Autoimmune Diseases (6) · Blood Coagulation Disorders (6) · Hemorrhage (6) · Infections (6) · Neoplasms (6) · Signs and Symptoms (6)
eltrombopag (13) · Thrombopoietin (3) · romiplostim (3) · Azacitidine (1) · Blood Specimen Collection (1) · Carboplatin (1) · Cyclophosphamide (1) · Cytarabine (1) · Inosine Triphosphate (1) · avatrombopag (1)
GlaxoSmithKline (9) · Amgen (2) · M.D. Anderson Cancer Center (2) · Novartis Pharmaceuticals (2) · Aydin Adnan Menderes University (1) · Christiana Care Health Services (1) · Dompé Farmaceutici S.p.A (1) · Hanny Al-Samkari, MD (1) · Kyowa Kirin Korea Co., Ltd. (1) · Medecins Sans Frontieres, Netherlands (1) · PrECOG, LLC. (1) · Shenzhen Second People's Hospital (1) · St. Jude Children's Research Hospital (1) · University Hospital, Bordeaux (1) · Wang Guorong (1)
United States (15) · France (8) · Germany (8) · Italy (8) · South Korea (8) · Taiwan (7) · Poland (6) · Russia (6) · Spain (6) · Canada (5) · Pakistan (5) · Puerto Rico (5) · United Kingdom (5) · Australia (4) · Belgium (4)
Alex Kline, MD (1) · David A. Paul, MD (1) · Flavio Mantelli, MD-PhD (1) · Gerald A Soff, MD (1) · Hanny Al-Samkari, MD (1) · Hillard M Lazarus, MD (1) · James B Bussel, M.D (1) · Khamraev A Karimovich, MD (1) · Najat C. Daw, M.D. (1) · Philipp du Cros, MBBS (1) · Saroj Vadhan-Raj, MD (1)
PMID 24126097, PMID 25777337, PMID 26173631, PMID 19231632, PMID 22409309, PMID 22913681, PMID 23492914, PMID 26686043, PMID 30305280, PMID 31183813, PMID 31474546, PMID 32476546, PMID 35554955, PMID 40593138